C
CEL-SCI Corp
AMEX:CVM
CEL-SCI Corp
AMEX:CVM
Price:
5.01
USD
-4.57%
Market Closed
Market Cap:
$40.2m
Relative Value
There is not enough data to reliably calculate the relative value of CVM.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CVM
Relative Value
Base Case
Not Available
Multiples Across Competitors
CVM Competitors Multiples
CEL-SCI Corp Competitors
CEL-SCI Corp Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
C
|
CEL-SCI Corp
AMEX:CVM
|
40.2m USD | 0 | -1.6 | -1.7 | -1.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
389.4B USD | 6.5 | 165.9 | 16.1 | 22.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197B USD | 5.4 | 25.5 | 14.7 | 14.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
193.8B USD | 6.7 | 23.9 | 16.3 | 16.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.6B USD | 10 | 31.8 | 23.3 | 24.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.4B USD | 5.7 | 18.2 | 13.7 | 15.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
73.7B AUD | 3.3 | 17 | 11.6 | 14.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43B EUR | 14.2 | 33.4 | 56.9 | 58.5 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
